Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
OMA 2026
Oral Semaglutide vs Orforglipron in Obesity – An Indirect Comparison
OMA 2026
OMA 2026
9 - 12 April 2026
Oral Semaglutide vs Orforglipron in Obesity – An Indirect Comparison
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Share
Copy link
{{pageUrl}}
Keywords
Obesity
Congress poster
GLP-1 RA
Semaglutide (oral)
RWE HEOR